Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

Glycophos must not be given undiluted.
Adults:
The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 ml of
Glycophos added to the infusion solution or to the admixture for which compatibility has been proved.
SPC 10-372, 2010-01-11 2 (4)
Infants:
The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/Kg body weight/day.

Glycophos should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly.
Glycophos must not be given undiluted.

No interactions with other drugs have been observed, but a moderate fall in serum phosphate can be seen during carbohydrate infusions.

Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.
No adverse events are to be expected when Glycophos is administered during pregnancy.

No effects on the ability to drive and use machines are to be expected.

No adverse effects related to glycerophosphate have been reported.

No adverse effects of an overdose have been reported. Most patients in need of intravenous nutrition have an increased capacity to handle glycerophosphate. See also 4.3 "Contraindications".

Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.

To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.

No pharmacokinetical data is available for infants, however with the recommended dosage
hyperphosphataemia is unlikely.

Preclinical safety studies on Glycophos demonstrated good tolerance.

Hydrochloric acid
Water for Injections

Glycophos may only be added to or mixed with other medicinal products for which compatibility has been documented. See 6.6.

Do not store above 25°C. Do not freeze.

Polypropylene vial.
Pack size: 10 x 20 ml

Glycophos must not be given undiluted.
Compatibility
Additions should be made aseptically.
SPC 10-372, 2010-01-11 4 (4)
Up to 120 ml of Glycophos and 48 mmol of calcium (as CaCl 2 ) can be added to 1000 ml
Vamin Glucose, Vamin 9 Electrolyte Free, Vamin 14, Vamin 14 Electrolyte Free, Vamin 18
Electrolyte Free and Vaminolact.
Up to 10 ml of Glycophos and 10 mmol of calcium (as CaCl 2 ) can be added to 1000 ml
Glucose 50 mg/ml.
Up to 20 ml of Glycophos and 20 mmol of calcium (as CaCl 2 ) can be added to1000 ml
Glucose 200 mg/ml.
Up to 60 mmol of Glycophos and 24 mmol of calcium (as CaCl 2 ) can be added to 1000 ml
Glucose 500 mg/ml.
Infusion time
The infusion time should not be less than 8 hours.
Stability
When additions are made to an infusion solution, the infusion should be completed within 24
hours from preparation to prevent microbiological contamination. The left over contents of
opened bottles/vials/ampoules should be discarded and not kept for later use.